Ensysce Biosciences, Inc. 8-K — AI Bull & Bear Analysis

Ensysce Biosciences finds itself at a crossroads following a formal notice from Nasdaq regarding its failure to satisfy continued listing requirements. The event creates a binary outcome for investors: either the company leverages this crisis to execute a rapid turnaround and regain compliance, or it succumbs to the liquidity pressures and faces a transition to the over-the-counter markets. The lack of a concrete remediation plan in the filing leaves the company's immediate future dependent on its ability to secure rapid capital or a strategic partner.